Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

In standard-risk acute promyelocytic leukemia, recent results have shown that all-trans retinoic acid plus arsenic trioxide combinations are at least as effective as classical all-trans retinoic acid plus anthracycline-based chemotherapy while being less myelosuppressive. However, the role of frontl...

Descripción completa

Detalles Bibliográficos
Autores principales: Adès, Lionel, Thomas, Xavier, Bresler, Agnes Guerci, Raffoux, Emmanuel, Spertini, Olivier, Vey, Norbert, Marchand, Tony, Récher, Christian, Pigneux, Arnaud, Girault, Stephane, Deconinck, Eric, Gardin, Claude, Tournilhac, Olivier, Lambert, Jean Francois, Chevallier, Patrice, de Botton, Stephane, Lejeune, Julie, Dombret, Hervé, Chevret, Sylvie, Fenaux, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269295/
https://www.ncbi.nlm.nih.gov/pubmed/30026341
http://dx.doi.org/10.3324/haematol.2018.198614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269295/
https://www.ncbi.nlm.nih.gov/pubmed/30026341
http://dx.doi.org/10.3324/haematol.2018.198614

Ejemplares similares